• Recruiting

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

car-gprc5d

NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia


This study is a single-center, open, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or plasma cell leukemia.


Sponsor

Chunrui Li


Collaborator

Nanjing IASO Biotechnology Co., Ltd


Information provided by (Responsible Party)

Chunrui Li, Tongji Hospital

 

ClinicalTrials.gov Identifier: NCT05219721

Official Title: An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

First Posted : February 2, 2022

Click here for details on ClinicalTrials.gov

 

Drug: CAR-T (CAR-GPRC5D)

 

Location

China, Hu Bei

 

RELATED GPRC5D POSTS


NCT04555551: Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma

Click here for details


NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS

Click here for details


NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Click here for details


NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

Click here for details

 

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details




Posts Archive